Comparison · NCT00424515-sae
Amplified KIT vs Mutated KIT: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Amplified KIT vs Mutated KIT: serious adverse events. Trial comparisons, record NCT00424515-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00424515-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0909 | 0.0162 | 0.377 | wilson | |
| Risk in group 2 | 0.231 | 0.0818 | 0.503 | wilson | |
| Risk difference, group 1 minus group 2 | -0.14 | -0.422 | 0.183 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.394 | 0.0475 | 3.27 | log | |
| Odds ratio, group 1 over group 2 | 0.333 | 0.0294 | 3.77 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Amplified KIT than on Mutated KIT | 7.15 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Amplified KIT | Imatinib was given at a dose of 400 mg orally daily (4 100 mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition. Patients were classified into two cohorts based upon KIT molecular status. | 1 | 11 | EG000 |
| Group 2 | Mutated KIT | Imatinib was given at a dose of 400 mg orally daily (4 100 mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition. Patients were classified into two cohorts based upon KIT molecular status. | 3 | 13 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- AE assessment occurred every other month from the start of study drug and up to day 30 post-treatment.
Source ClinicalTrials.gov
Trial
- Title
- Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
- NCT number
- NCT00424515
- Phases
- PHASE2
- Conditions
- Mucosal Melanoma, Acral/Lentiginous Melanoma, Chronically Sun Damaged Melanomas
- Interventions
- Imatinib
- Lead sponsor
- Dana-Farber Cancer Institute
- Results first posted
- 2016-12-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00424515?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00424515-sae